Nutrigenomics and inflammatory bowel diseases

Expert Review of Clinical Immunology

Volumn 6, Issue 4, 2010, Pages 573-583

  Ferguson, Lynnette R ^a  

^a UNIVERSITY OF AUCKLAND   (New Zealand)

Author keywords

Crohns disease; nutrigenetics; nutrigenomics; polyunsaturated fatty acids; ulcerative colitis; vitamin D.

Indexed keywords

ADAPTIVE IMMUNITY; AUTOPHAGY; BACTERIUM; CASE CONTROL STUDY; CROHN DISEASE; DIET; DISEASE COURSE; ENTERITIS; ENVIRONMENT; GENE EXPRESSION; GENE INTERACTION; GENETIC SUSCEPTIBILITY; GENETIC VARIABILITY; HUMAN; INTESTINE MUCOSA PERMEABILITY; MYCOBACTERIUM TUBERCULOSIS; NONHUMAN; NUTRIGENOMICS; NUTRITIONAL REQUIREMENT; PATTERN RECOGNITION; PREVALENCE; REVIEW; SALMONELLA TYPHIMURIUM; SECONDARY IMMUNE RESPONSE; ULCERATIVE COLITIS;

ADAPTIVE IMMUNITY; ANIMALS; COLITIS, ULCERATIVE; CROHN DISEASE; GENETIC PREDISPOSITION TO DISEASE; GENETIC VARIATION; HUMANS; INFLAMMATORY BOWEL DISEASES; NUTRIGENOMICS; NUTRITION THERAPY;

EID: 77954398661     PISSN: 1744666X     EISSN: None     Source Type: Journal    
DOI: 10.1586/eci.10.43     Document Type: Review

References (151)

1. Afman L, Muller M. Nutrigenomics: from molecular nutrition to prevention of disease. J. Am. Diet Assoc. 106(4), 569-576 (2006).
2. Ekbom A. Twin studies in IBD and other disorders. J. Pediatr. Gastroenterol. Nutr. 46(Suppl. 1), E9 (2008).
3. Woolner JT, Parker TJ, Kirby GA, Hunter JO. The development and evaluation of a diet for maintaining remission in Crohn's disease. J. Hum. Nutr. Diet. 11(1), 1-11 (1998).
4. Baker PI, Love DR, Ferguson LR. Role of gut microbiota in Crohn's disease. Expert Rev. Gastroenterol. Hepatol. 3(5), 535-546 (2009).
5. Jowett SL, Seal CJ, Pearce MS et al Infuence of dietary factors on the clinical course of ulcerative colitis: a prospective cohort study. Gut 53(10), 1479-1484 (2004).
6. Petermann I, Triggs CM, Huebner C et al Mushroom intolerance: a novel diet-gene interaction in Crohn's disease. Br. J. Nutr. 102(4), 506-508 (2009).
7. Barnett M, Bermingham E, McNabb W et al. Investigating micronutrients and epigenetic mechanisms in relation to infammatory bowel disease. Mutat. Res. DOI: 10.1016/j.mrfmmm.2010.02.006 (2010) (In Press).
8. van Limbergen J, Wilson DC, Satsangi J. The genetics of Crohn's disease. Annu. Rev. Genomics Hum. Genet. 10, 89-116 (2009).
9. Ferguson LR, Philpott M, Dryland P. Nutrigenomics in the whole-genome scanning era: Crohn's disease as example. Cell. Mol. Life Sci. 64(23), 3105-3118 (2007). (Pubitemid 351152239)
10. Mathews C. New links to the pathogenesis of Crohn disease provided by genome-wide association scans. Nat. Rev. Genet. 9(1), 9-14 (2008).
11. Kugathasan S, Baldassano RN, Bradfeld JP et al. Loci on 20q13 and 21q22 are associated with pediatric-onset infammatory bowel disease. Nat. Genet. 40(10), 1211-1215 (2008).
12. Hugot JP, Chamaillard M, Zouali H et al Association of NOD2 leucine-rich repeat variants with susceptibility to Crohn's disease. Nature 411(6837), 599-603 (2001). (Pubitemid 32531408)
13. Ogura Y, Bonen DK, Inohara N et al. A frameshift mutation in NOD2 associated with susceptibility to Crohn's disease. Nature 411(6837), 603-606 (2001). (Pubitemid 32531409)
14. Girardin SE, Boneca, IG, Viala J et al. Nod2 is a general sensor of peptidoglycan through muramyl dipeptide (MDP) detection. J. Biol. Chem. 278(11), 8869-8872 (2003). (Pubitemid 36800360)
15. Gearry RB, Richardson A, Frampton C et al. High incidence of Crohn's disease in Canterbury, New Zealand: results of an epidemiologic study. Infamm. Bowel Dis. 12(10), 936-943 (2006).
16. Hugot JP. CARD15/NOD2 mutations in Crohn's disease. Ann. NY Acad. Sci. 1072(1), 9-18 (2006).
17. Philpott M, Mackay L, Ferguson LR, Forbes D, Skinner M. Cell culture models in developing nutrigenomics foods for infammatory bowel disease. Mutation Res. 622(1-2), 94-102 (2007). (Pubitemid 47211178)
18. Huebner C, Ferguson LR, Han DY et al. Nucleotide-binding oligomerization domain containing 1 (NOD1) haplotypes and single nucleotide polymorphisms modify susceptibility to infammatory bowel diseases in a New Zealand Caucasian population: a case-control study. BMC Res. Notes 2, 52 (2009).
19. Arbour NC, Lorenz E, Schutte BC et al. TLR4 mutations are associated with endotoxin hyporesponsiveness in humans. Nat Genet. 25(2), 187-191 (2000). (Pubitemid 30394990)
20. Browning B, Huebner C, Petermann I et al. Has Toll-like receptor 4 been prematurely rejected as an infammatory bowel disease gene? Association study combined with meta-analysis shows strong evidence for association. Am. J. Gastroenterol. 102(11), 2504-2512 (2007). (Pubitemid 47631777)
21. Ferguson L, Browning BL, Huebner C et al. Single nucleotide polymorphisms in human Paneth cell defensin A5 may confer susceptibility to infammatory bowel disease in a New Zealand Caucasian population. Dig. Liver Dis. 40(9), 723-730 (2008).
22. Petermann I, Huebner C, Browning BL et al. Interactions among genes infuencing bacterial recognition increase IBD risk in a population-based New Zealand cohort. Hum. Immunol. 70(6), 440-446 (2009).
23. Rioux JD, Ramnik JX, Taylor KD et al. Genome-wide association study identifes new susceptibility loci for Crohn disease and implicates autophagy in disease pathogenesis. Nat. Genet. 39(5), 596-604 (2007).
24. Hampe J, Franke A, Rosenstiel P et al. A genome-wide association scan of nonsynonymous SNPs identifes a susceptibility variant for Crohn disease in ATG16L1. Nat Genet. 39(2), 207-211 (2007). (Pubitemid 46184351)
25. Reis E, Sousa C. Immunology: eating in to avoid infection. Science 315(5817), 1376-1377 (2007).
26. Lee HK, Lund JM, Ramanathan B, Mizushima N, Iwasaki A. Autophagy-dependent viral recognition by plasmacytoid dendritic cells. Science 315(5817), 1398-1401 (2007). (Pubitemid 46399546)
27. Mizushima N, Klionsky D. Protein turnover via autophagy: implications for metabolism. Annu. Rev. Nutr. 27, 19-40 (2007). (Pubitemid 351373346)
28. Sinsimer D, Fallows D, Peixoto B, Krahenbuhl J, Kaplan G, Manca C. Mycobacterium leprae actively modulates the cytokine response in naive human monocytes. Infect. Immun. 78(1), 293-300 (2010).
29. Travassos L, Carneiro LA, Girardin S, Philpott DJ. Nod proteins link bacterial sensing and autophagy. Autophagy 6(3), 409-411 (2010).
30. Travassos L, Carneiro LA, Ramjeet M et al. Nod1 and Nod2 direct autophagy by recruiting ATG16L1 to the plasma membrane at the site of bacterial entry. Nat. Immunol. 11(1), 55-62 (2010).
31. Cooney R, Baker J, Brain O et al. NOD2 stimulation induces autophagy in dendritic cells infuencing bacterial handling and antigen presentation. Nat. Med. 16(1), 90-97 (2010).
32. Duerr RH, Taylor KD, Brant SR et al. A genome-wide association study identifes IL23R as an infammatory bowel disease gene. Science 314(5804), 1461-1463 (2006).
33. Xavier RJ, Podolsky DK. Unravelling the pathogenesis of infammatory bowel disease. Nature 448(7152), 427-434 (2007).
34. Barrett JC, Hansoul S, Nicolae DL et al. Genome-wide association defnes more than 30 distinct susceptibility loci for Crohn's disease. Nat. Genet. 40(8), 955-962 (2008).
35. Ferguson L, Han DY, Fraser AG et al. Genetic factors in chronic infammation: single nucleotide polymorphisms in the STAT-JAK pathway, susceptibility to DNA damage and Crohn's disease in a New Zealand population. Mutat. Res. (2010) DOI: 10.1016/j.mrfmmm.2010.01.017 (Epub ahead of print).
36. Ferguson LR, Huebner C, Petermann I et al. Single nucleotide polymorphism in the tumor necrosis factor-a gene affects infammatory bowel diseases risk. World J. Gastroenterol. 14(29), 4652-4661 (2008).
37. Fisher SA, Tremelling M, Anderson CA et al. Genetic determinants of ulcerative colitis include the ECM1 locus and fve loci implicated in Crohn's disease. Nat. Genet. 40(6), 710-712 (2008). (Pubitemid 351748865)
38. Fernando MM, Stevens CR, Walsh EC et al. Defning the role of the MHC in autoimmunity: a review and pooled analysis. PLoS Genetics. 4(4), e1000024 (2008).
39. Wang S, Raven JF, Baltzis D et al. The catalytic activity of the eukaryotic initiation factor-2 a kinase PKR is required to negatively regulate Stat1 and Stat3 via activation of the T-cell protein-tyrosine phosphatase. J. Biol. Chem. 281, 9439-9449 (2006). (Pubitemid 43864661)
40. Lu X, Chen J, Sasmono RT et al. T-cell protein tyrosine phosphatase, distinctively expressed in activated-B-cell-like diffuse large B-cell lymphomas, is the nuclear phosphatase of STAT6. Mol. Cell. Biol. 27(6), 2166-2179 (2007). (Pubitemid 46418473)
41. Amre DK, Mack DR, Morgan K et al. Investigation of reported associations between the 20q13 and 21q22 loci and pediatric-onset Crohn's disease in Canadian children. Am. J. Gastroenterol. 140(11), 2824-2828 (2009).
42. Glocker E, Kotlarz D, Boztug K et al. Infammatory bowel disease and mutations affecting the interleukin-10 receptor. N. Engl. J. Med. 361(21), 2033-2045 (2009).
43. Goyette P, Lefebvre C, Ng A et al. Gene-centric association mapping of chromosome 3p implicates MST1 in IBD pathogenesis. Mucosal Immunol. 1(2), 131-138 (2008).
44. Peltekova VD, Wintle RF, Rubin LA et al. Functional variants of OCTN cation transporter genes are associated with Crohn disease. Nat Genet. 36(5), 471-475 (2004).
45. Ferguson L, Han DY, Huebner C et al. Single nucleotide polymorphisms in IL4, OCTN1 and OCTN2 genes in association with infammatory bowel disease phenotypes in a Caucasian population in Canterbury, New Zealand. The Open Gastroenterology Journal 2(7), 50-56 (2008).
46. Stoll M, Corneliussen B, Costello CM et al. Genetic variation in DLG5 is associated with infammatory bowel disease. Nat. Genet. 36(5), 476-480 (2004). (Pubitemid 38620031)
47. Browning B, Annese V, Barclay ML et al. Gender-stratifed analysis of DLG5 R30Q in 4707 Crohn's disease patients and 4973 controls from 12 Caucasian cohorts. J. Med.Genet. 45, 36-42 (2008). (Pubitemid 351158157)
48. Festen EA, Stokkers PC, van Diemen CC et al. Genetic analysis in a Dutch study sample identifes more ulcerative colitis susceptibility loci and shows their additive role in disease risk. Am. J. Gastroenterol. 105(2), 395-402 (2010).
49. Franke A, Balschun T, Karlsen TH et al. Sequence variants in IL10, ARPC2 and multiple other loci contribute to ulcerative colitis susceptibility. Nat. Genet. 40(11), 1319-1323 (2008).
50. Glas J, Stallhofer J, Ripke S et al. Novel genetic risk markers for ulcerative colitis in the IL2/IL21 region are in epistasis with IL23R and suggest a common genetic background for ulcerative colitis and celiac disease. Am. J. Gastroenterol. 104(7), 1737-1744 (2009).
51. Huebner C, Petermann I, Browning BL et al. Genetic association study of MDR1 and infammatory bowel disease reveals partial protective effect of heterozygous variants in ulcerative colitis. Infamm. Bowel Dis. 15(12), 1784-1793 (2009).
52. Juyal G, Midha V, Amre D, Sood A, Seidman E, Thelma BK. Associations between common variants in the MDR1 (ABCB1) gene and ulcerative colitis among North Indians. Pharmacogenet. Genomics 19(1), 77-85 (2009).
53. Lees CW, Satsangi J. Genetics of infammatory bowel disease: implications for disease pathogenesis and natural history. Expert Rev. Gastroenterol. Hepatol. 3(5), 513-534 (2009).
54. Lee G, Buchman AL. DNA-driven nutritional therapy of infammatory bowel disease. Nutrition 25(9), 885-891 (2009).
55. Stardelova G, Misevska P, Zdravkovska M, Trajkov D, Serafmoski V. Total parenteral nutrition in treatment of patients with infammatory bowel disease. Prilozi 29(1), 21-43 (2008).
56. Geerling B, Badart-Smook A, Stockbrugger RW, Brummer RJ. Comprehensive nutritional status in recently diagnosed patients with infammatory bowel disease compared with population controls. Eur. J. Clin. Nutr. 54(6), 514-521 (2000). (Pubitemid 30345403)
57. Geerling BJ, Dagnelie PC, Badart-Smook A, Russel MG, Stockbrügger RW, Brummer R. Diet as a risk factor for the development of ulcerative colitis. Am. J. Gastroenterol. 95(4), 1008-1013 (2000). (Pubitemid 30196738)
58. Russel MG, Engels LG, Muris J W et al. Modern life in the epidemiology of infammatory bowel disease: a case-control study with special emphasis on nutritional factors. Eur. J. Gastroenterol. Hepatol. 10(3), 243-249 (1998).
59. Triggs C, Munday K, Hu R et al. Dietary factors in chronic infammation: food tolerances and intolerances of a New Zealand Caucasian Crohn's disease population. Mutat. Res. DOI: 10.1016/j. mrfmmm.2010.01.020 (2010) (Epub ahead of print). Scalabrino G. Vitamin-regulated cytokines and growth factors in the CNS and elsewhere. J. Neurochem. 111(6), 1309-1326 (2009).
60. Lionetti P, Callegari ML, Ferrari S et al. Enteral nutrition and microfora in pediatric Crohn's disease. J. Parenter. Enteral. Nutr. 29(4), S173-S175; discussion S175-S178 (2005).
61. Jones JL, Foxx-Orenstein AE. The role of probiotics in infammatory bowel disease. Dig. Dis. Sci. 52(3), 607-611 (2007). (Pubitemid 46303048)
62. Lim CC, Ferguson LR, Tannock GW Dietary fbres as 'prebiotics': implications for colorectal cancer. Mol. Nutr. Food Res. 49(6), 609-619 (2005).
63. Baines K, Wood LG, Gibson PG. The nutrigenomics of asthma: molecular mechanisms of airway neutrophilia following dietary antioxidant withdrawal. OMICS 3(5), 355-365 (2009).
64. Philpott M, Mackay L, Ferguson LR, Forbes D, Skinner M. Cell culture models in developing nutrigenomics foods for infammatory bowel disease. Mutat. Res. 622(1-2), 94-102 (2007). (Pubitemid 47211178)
65. Wang T, Dabbas B, Laperriere D et al. Direct and indirect induction by 1,25-dihydroxyvitamin D of the 3 NOD2/CARD15-defensin b2 innate immune pathway defective in Crohn disease. J. Biol. Chem. 285, 2227-2231 (2010).
66. Leung CH, Lam W, Ma DL, Gullen EA, Cheng YC. Butyrate mediates nucleotide-binding and oligomerisation domain (NOD) 2-dependent mucosal immune responses against peptidoglycan. Eur. J. Immunol. 39(12), 3529-3537 (2009).
67. Borthakur A, Bhattacharyya S, Dudeja PK, Tobacman JK. Carrageenan induces interleukin-8 production through distinct Bcl10 pathway in normal human colonic epithelial cells. Am. J. Physiol. Gastrointest. Liver Physiol. 292(3), G829-G838 (2007). (Pubitemid 46440382)
68. Cukovic-Cavka S, Likic R, Francetic I, Rustemovic N, Opacic M, Vucelic B. Lactobacillus acidophilus as a cause of liver abscess in a NOD2/CARD15-positive patient with Crohn's disease. Digestion 73(2-3), 107-110 (2006). (Pubitemid 44155911)
69. Sadeghi K, Wessner B, Laggner U et al Vitamin D3 down-regulates monocyte TLR expression and triggers hypo responsiveness to pathogen-associated molecular patterns. Eur. J. Immunol. 36(2), 361-370 (2006). (Pubitemid 43257459)
70. Simmons JD, Mullighan C, Welsh KI, Jewell DP. Vitamin D receptor gene polymorphism: association with Crohn's disease susceptibility. Gut 47(2), 211-214 (2000). (Pubitemid 30489764)
71. Martin K, Radlmayr M, Borchers R, Heinzlmann M, Folwaczny C. Candidate genes colocalized to linkage regions in infammatory bowel disease. Digestion 66(2), 121-126 (2002). (Pubitemid 35356692)
72. Kadowaki M, Karim, MR, Carpi A, Miotto G. Nutrient control of macro auto phagy in mammalian cells. Mol Aspects Med. 27(5-6), 426-443 (2006). (Pubitemid 44479873)
73. Scherz-Shouval R, Shvets E, Fass E, Shorer H, Gil L, Elazar Z. Reactive oxygen species are essential for autophagy and specifcally regulate the activity of Atg4. EMBO J. 26(7), 1749-1760 (2007). (Pubitemid 46624042)
74. Gossner G, Choi M, Tan L et al. Genistein-induced apoptosis and autophagocytosis in ovarian cancer cells. Gynecol. Oncol 105(1), 23-30 (2007). (Pubitemid 46441453)
75. Hazan R, Levine A, Abeliovich H. Benzoic acid, a weak organic acid food preservative, exerts specifc effects on intracellular membrane traffcking pathways in Saccharomyces cerevisiae. Appl. Environ. Microbiol. 70(8), 4449-4457 (2004). (Pubitemid 39095462)
76. Onodera J, Ohsumi Y. Autophagy is required for maintenance of amino acid levels and protein synthesis under nitrogen starvation. J. Biol. Chem. 280(36), 31582-31586 (2005). (Pubitemid 41291902)
77. Zachos M, Tondeur M, Griffths AM. Enteral nutritional therapy for induction of remission in Crohn's disease. Cochrane Database Syst. Rev. 24(1), CD000542 (2007). (Pubitemid 351835440)
78. Kim J, Yoon M, Jie C. Signal transducer and activator of transcription 3 (STAT3) mediates amino acid inhibition of insulin signalling through serine 727 phosphorylation. J. Biol. Chem. 284(51), 35425-35432 (2009).
79. Xie L, Li XK, Funeshima-Fuji N et al Amelioration of experimental autoimmune encephalomyelitis by curcumin treatment through inhibition of IL-17 production. Int. Immunopharmacol. 9(5), 575-581 (2009).
80. Danesi F, Philpott M, Huebner C, Bordoni A, Ferguson LR. Food-derived bioactives as potential regulators of the IL-12/IL-23 pathway implicated in infammatory bowel diseases. Mutat. Res. DOI: 10.1016/j.mrfmmm.2010.01.001 (2010) (In Press).
81. Guerreiro CS, Ferreira P, Tavares L et al. Fatty acids, IL6, and TNFa polymorphisms: an example of nutrigenetics in Crohn's disease. Am. J. Gastroenterol. 104(9), 2241-2249 (2009).
82. Fontaine-Bisson B, El-Sohemy A. Genetic polymorphisms of tumor necrosis factor-a modify the association between dietary polyunsaturated fatty acids and plasma high-density lipoprotein-cholesterol concentrations in a population of young adults. J. Nutrigenet. Nutrigenomics 1(5), 215-223 (2008).
83. Castagnini C, Luceri C, Toti S et al. Reduction of colonic infammation in HLA-B27 transgenic rats by feeding Marie Ménard apples, rich in polyphenols. Br. J. Nutr. 102(11), 1620-1628 (2009).
84. Kimchi-Sarfaty C, Oh JM, Kim IW et al. A 'silent' polymorphism in the MDR1 gene changes substrate specifcity. Science 315(5811), 525-528 (2007).
85. Ferguson LR, De Flora S. Multiple drug resistance, antimutagenesis and anticarcinogenesis. Mutat. Res. 591(1-2), 24-33 (2005). (Pubitemid 41654837)
86. -/-) mice, a model of infammatory bowel diseases. Br. J. Nutr. 101(2), 169-181 (2009).
87. Roy N, Barnett M, Knoch B, Dommels Y, McNabb W. Nutrigenomics applied to an animal model of infammatory bowel diseases: transcriptomic analysis of the effects of eicosapentaenoic acid-and arachidonic acid-enriched diets. Mutation Res. 622(1-2), 103-116 (2007). (Pubitemid 47224954)
88. Kornman K, Rogus J, Roh-Schmidt H et al. Interleukin-1 genotype-selective inhibition of infammatory mediators by a botanical: a nutrigenetics proof of concept. Nutrition 23, 844-852 (2007). (Pubitemid 47532396)
89. Feuk L. Inversion variants in the human genome: role in disease and genome architecture. Genome Med. 2(2), 11 (2010).
90. Stankiewicz P, Lupski JR. Structural variation in the human genome and its role in disease. Annu. Rev. Med. 61, 437-455 (2010).
91. Dalca AV, Brudno M. Genome variation discovery with high-throughput sequencing data. Brief Bioinform. 11(1), 3-14 (2010).
92. Eleftherohorinou H, Wright V, Hoggart C et al. Pathway analysis of GWAS provides new insights into genetic susceptibility to 3 infammatory diseases. PLoS One 4(11), e8068 (2009).
93. Lin HM, Barnett M, Roy N et al. Metabolomic analysis identifes infammatory and non-infammatory metabolic effects of genetic modifcation in a mouse model of Crohn's disease. J. Proteome Res. 9(4), 1965-1975 (2010).
94. Abraham C, Cho JH. Infammatory bowel disease. N. Engl. J. Med. 361(21), 2066-2078 (2009).
95. Monteleone G, Caprioli F. T-cell-directed therapies in infammatory bowel diseases. Clin. Sci. (Lond.) 118(12), 707-715 (2010).
96. Monteleone G, Biancone L, Marasco R et al. Interleukin 12 is expressed and actively released by Crohn's disease intestinal lamina propria mononuclear cells. Gastroenterology 112(4), 1169-1178 (1997). (Pubitemid 27157528)
97. Neurath MF, Weigmann B, Finotto S et al. The transcription factor T-bet regulates mucosal T cell activation in experimental colitis and Crohn's disease. J. Exp. Med. 195(9), 1129-1143 (2002). (Pubitemid 34517139)
98. + lamina propria (LP) lymphokine secretion profles in infammatory bowel disease. Crohn's disease LP cells manifest increased secretion of IFN-g, whereas ulcerative colitis LP cells manifest increased secretion of IL-5. J. Immunol. 157(3), 1261-1270 (1996).
99. Fuss IJ, Heller F, Boirivant M et al. Nonclassical CD1d-restricted NK T cells that produce IL-13 characterize an atypical Th2 response in ulcerative colitis. J. Clin. Invest. 113(10), 1490-1497 (2004). (Pubitemid 39071705)
100. Heller F, Florian P, Bojarski C et al. Interleukin-13 is the key effector Th2 cytokine in ulcerative colitis that affects epithelial tight junctions, apoptosis, and cell restitution. Gastroenterology 129(2), 550-564 (2005). (Pubitemid 41096643)
101. Fujino S, Andoh A, Bamba S et al. Increased expression of interleukin 17 in infammatory bowel disease. Gut 52(1), 65-70 (2003). (Pubitemid 36020767)
102. Sarra M, Pallone F, Macdonald TT, Monteleone G. IL-23/IL-17 axis in IBD. Infamm. Bowel Dis. DOI: 10.1002/ibd.21248 (2010) (Epub ahead of print).
103. Strober W, Fuss IJ, Blumberg RS. The immunology of mucosal models of infammation. Annu. Rev. Immunol. 20, 495-549 (2002).
104. Parrish-Novak J, Dillon SR, Nelson A et al. Interleukin 21 and its receptor are involved in NK cell expansion and regulation of lymphocyte function. Nature 408(6808), 57-63 (2000).
105. Coquet JM, Kyparissoudis K, Pellicci DG et al. IL-21 is produced by NKT cells and modulates NKT cell activation and cytokine production. J. Immunol. 178(5), 2827-2834 (2007). (Pubitemid 46333160)
106. Chtanova T, Tangye SG, Newton R et al T follicular helper cells express a distinctive transcriptional profle, refecting their role as non-Th1/Th2 effector cells that provide help for B cells. J. Immunol. 173(1), 68-78 (2004). (Pubitemid 38797327)
107. Vogelzang A, McGuire HM, Yu D et al. A fundamental role for interleukin-21 in the generation of T follicular helper cells. Immunity 29(1), 127-137 (2008).
108. Zhou L, Ivanov, II, Spolski R et al. IL-6 programs T(H)-17 cell differentiation by promoting sequential engagement of the IL-21 and IL-23 pathways. Nat. Immunol. 8(9), 967-974 (2007). (Pubitemid 47300011)
109. Korn T, Bettelli E, Gao W et al. IL-21 initiates an alternative pathway to induce proinfammatory T(H)17 cells. Nature 448(7152), 484-487 (2007). (Pubitemid 47123515)
110. Nurieva R, Yang XO, Martinez G et al Essential autocrine regulation by IL-21 in the generation of infammatory T cells. Nature 448(7152), 480-483 (2007). (Pubitemid 47123514)
111. Strengell M, Matikainen S, Siren J et al IL-21 in synergy with IL-15 or IL-18 enhances IFN-g production in human NK and T cells. J. Immunol. 170(11), 5464-5469 (2003). (Pubitemid 36617833)
112. Kim HP, Korn LL, Gamero AM, Leonard WJ. Calcium-dependent activation of interleukin-21 gene expression in T cells. J. Biol. Chem. 280(26), 25291-25297 (2005). (Pubitemid 40934624)
113. Mehta DS, Wurster AL, Weinmann AS, Grusby MJ. NFATc2 and T-bet contribute to T-helper-cell-subset-specifc regulation of IL-21 expression. Proc. Natl Acad. Sci. USA 102(6), 2016-2021 (2005).
114. Korn T, Bettelli E, Oukka M, Kuchroo VK. IL-17 and Th17 cells. Annu. Rev. Immunol. 27, 485-517 (2009).
115. Huber M, Brustle A, Reinhard K et al. IRF4 is essential for IL-21-mediated induction, amplifcation, and stabilization of the Th17 phenotype. Proc. Natl Acad. Sci. USA 105(52), 20846-20851 (2008).
116. Ho IC, Lo D, Glimcher LH. c-maf promotes T helper cell type 2 (Th2) and attenuates Th1 differentiation by both interleukin 4-dependent and-independent mechanisms. J. Exp. Med. 188(10), 1859-1866 (1998). (Pubitemid 28536773)
117. Bauquet AT, Jin H, Paterson AM et al. The costimulatory molecule ICOS regulates the expression of c-Maf and IL-21 in the development of follicular T helper cells and Th-17 cells. Nat. Immunol. 10(2), 167-175 (2009).
118. Asao H, Okuyama C, Kumaki S et al. Cutting edge: the common g-chain is an indispensable subunit of the IL-21 receptor complex. J. Immunol. 167(1), 1-5 (2001). (Pubitemid 32567752)
119. Spolski R, Leonard WJ. Interleukin-21: basic biology and implications for cancer and autoimmunity. Annu. Rev. Immunol. 26, 57-79 (2008). (Pubitemid 351600371)
120. Monteleone G, Pallone F, MacDonald TT. Interleukin-21: a critical regulator of the balance between effector and regulatory T-cell responses. Trends Immunol. 29(6), 290-294 (2008).
121. Jungel A, Distler JH, Kurowska-Stolarska M et al. Expression of interleukin-21 receptor, but not interleukin-21, in synovial fbroblasts and synovial macrophages of patients with rheumatoid arthritis. Arthritis Rheum. 50(5), 1468-1476 (2004). (Pubitemid 38608068)
122. Distler JH, Jungel A, Kowal-Bielecka O et al. Expression of interleukin-21 receptor in epidermis from patients with systemic sclerosis. Arthritis Rheum. 52(3), 856-864 (2005). (Pubitemid 40365109)
123. Monteleone G, Caruso R, Fina D et al. Control of matrix metalloproteinase production in human intestinal fbroblasts by interleukin 21. Gut 55(12), 1774-1780 (2006). (Pubitemid 44893577)
124. Caruso R, Fina D, Peluso I et al. A functional role for interleukin-21 in promoting the synthesis of the T-cell chemoattractant, MIP-3a, by gut epithelial cells. Gastroenterology 132(1), 166-175 (2007). (Pubitemid 46108732)
125. Ozaki K, Kikly K, Michalovich D, Young PR, Leonard WJ. Cloning of a type I cytokine receptor most related to the IL-2 receptor b chain. Proc. Natl Acad. Sci. USA 97(21), 11439-11444 (2000).
126. Jin H, Carrio R, Yu A, Malek TR. Distinct activation signals determine whether IL-21 induces B cell costimulation, growth arrest, or Bim-dependent apoptosis. J. Immunol. 173(1), 657-665 (2004). (Pubitemid 38797396)
127. Zeng R, Spolski R, Casas E et al. The molecular basis of IL-21-mediated proliferation. Blood 109(10), 4135-4142 (2007). (Pubitemid 46743374)
128. Fuqua CF, Akomeah R, Price JO, Adunyah SE. Involvement of ERK-1/2 in IL-21-induced cytokine production in leukemia cells and human monocytes. Cytokine 44(1), 101-107 (2008).
129. Spolski R, Leonard WJ. The Yin and Yang of interleukin-21 in allergy, autoimmunity and cancer. Curr. Opin. Immunol. 20(3), 295-301 (2008). (Pubitemid 351600371)
130. Monteleone G, Monteleone I, Fina D et al. Interleukin-21 enhances T-helper cell type I signaling and interferon-g production in Crohn's disease. Gastroenterology 128(3), 687-694 (2005). (Pubitemid 40585371)
131. Yamamoto-Furusho JK, Miranda-Perez E, Fonseca-Camarillo G et al. Interleukin 21 expression is increased in rectal biopsies from patients with ulcerative colitis. Infamm. Bowel Dis. 16(7), 1090 (2010).
132. Sarra M, Monteleone I, Stolf C et al. Interferon-g-expressing cells are a major source of interleukin-21 in infammatory bowel diseases. Infamm. Bowel Dis. DOI: 10.1002/ibd.21238 (2010) (Epub ahead of print).
133. van Heel DA, Franke L, Hunt KA et al. A genome-wide association study for celiac disease identifes risk variants in the region harboring IL2 and IL21. Nat. Genet. 39(7), 827-829 (2007). (Pubitemid 47014494)
134. Festen EA, Goyette P, Scott R et al. Genetic variants in the region harbouring IL2/IL21 associated with ulcerative colitis. Gut 58(6), 799-804 (2009).
135. Asano K, Ikegami H, Fujisawa T et al. Molecular scanning of interleukin-21 gene and genetic susceptibility to type 1 diabetes. Hum. Immunol. 68(5), 384-391 (2007). (Pubitemid 46616978)
136. Liu Y, Helms C, Liao W et al. A genome-wide association study of psoriasis and psoriatic arthritis identifes new disease loci. PLoS Genet. 4(3), e1000041 (2008). (Pubitemid 351656703)
137. Chatterjee R, Batra J, Ghosh B. A common exonic variant of interleukin 21 confers susceptibility to atopic asthma. Int. Arch. Allergy Immunol. 148(2), 137-146 (2009).
138. Sawalha AH, Kaufman KM, Kelly JA et al. Genetic association of interleukin-21 polymorphisms with systemic lupus erythematosus. Ann. Rheum. Dis. 67(4), 458-461 (2008). (Pubitemid 351498423)
139. Caruso R, Fina D, Peluso I et al. IL-21 is highly produced in Helicobacter pylori-infected gastric mucosa and promotes gelatinases synthesis. J. Immunol. 178(9), 5957-5965 (2007). (Pubitemid 46674393)
140. Fina D, Sarra M, Caruso R et al. Interleukin 21 contributes to the mucosal T helper cell type 1 response in coeliac disease. Gut 57(7), 887-892 (2008). (Pubitemid 351919521)
141. Fina D, Sarra M, Fantini MC et al. Regulation of gut infammation and Th17 cell response by interleukin-21. Gastroenterology 134(4), 1038-1048 (2008). (Pubitemid 351451986)
142. Caprioli F, Sarra M, Caruso R et al. Autocrine regulation of IL-21 production in human T lymphocytes. J. Immunol. 180(3), 1800-1807 (2008).
143. Kwon JH, Keates S, Bassani L, Mayer LF, Keates AC. Colonic epithelial cells are a major site of macrophage infammatory protein 3a (MIP-3a) production in normal colon and infammatory bowel disease. Gut 51(6), 818-826 (2002). (Pubitemid 35408603)
144. Wang C, Kang SG, Lee J, Sun Z, Kim CH. The roles of CCR6 in migration of Th17 cells and regulation of effector T-cell balance in the gut. Mucosal Immunol. 2(2), 173-183 (2009).
145. Liu Z, Yang L, Cui Y et al. Il-21 enhances NK cell activation and cytolytic activity and induces Th17 cell differentiation in infammatory bowel disease. Infamm. Bowel Dis. 15(8), 1133-1144 (2009).
146. Spolski R, Kim HP, Zhu W, Levy DE, Leonard WJ. IL-21 mediates suppressive effects via its induction of IL-10. J. Immunol. 182(5), 2859-2867 (2009).
147. Kishida T, Hiromura Y, Shin-Ya M et al. IL-21 induces inhibitor of differentiation 2 and leads to complete abrogation of anaphylaxis in mice. J. Immunol. 179(12), 8554-8561 (2007).
148. Hiromura Y, Kishida T, Nakano H et al. IL-21 administration into the nostril alleviates murine allergic rhinitis. J. Immunol. 179(10), 7157-7165 (2007).
149. Elsaesser H, Sauer K, Brooks DG. IL-21 is required to control chronic viral infection. Science 324(5934), 1569-1572 (2009).
150. Andorsky DJ, Timmerman JM. Interleukin-21: biology and application to cancer therapy. Expert Opin. Biol. Ther. 8(9), 1295-1307 (2008).
151. + T cell expansion and is not required for tumor immunity. J. Immunol. 183(11), 7326-7336 (2009).